CARE: Lupus



Start Date:


End Date:




Max Credits:


Credit Type:




Program Information

This online self-assessment tool is designed to test the rheumatology knowledge base of physicians. This module consists of 30 case-based questions with answer rationales, images and educational reference links.


Registration Fees

  • Members: $50 
  • Non-Members: $50
  • FIT Members: $25
  • FIT Non-Members: $50
  • Program Director Members*: $25

*Program Directors please email to receive the $25 rate.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The ACR designates this enduring material for a maximum of 10 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claim MOC Points

  • Select the MOC checkbox to claim MOC points equal to the number of CME hours claimed.
  • MOC points are submitted to ABIM each day at 11:30 PM EST. After points are submitted, ABIM will not accept changes.
  • If you are submitting MOC points, check your ABIM Physician Portal 24 - 48 hours after submission to make sure your MOC points are reflected.

Learning Objectives
Upon completion of this activity, learners should be able to:

  • Recognize the varied clinical manifestations and systemic symptoms in patients with lupus
  • Weigh treatment considerations in patients with lupus, including lupus in pregnancy and lupus nephritis
  • Evaluate indications and adverse effects of medications used to treat lupus
  • Appreciate health disparities that contribute to outcomes in lupus
  • Recognize the immunology and pathophysiology that drives the clinical manifestations seen in lupus
  • Address health maintenance considerations specific to patients with lupus

Release Date: August 24, 2015

Expiration Date: August 23, 2018



Use of Professional Judgment
The CARE Program, including all educational links is intended to be used as a tool to assess the rheumatology base medical knowledge of the learner. The information presented relates to basic principles of diagnosis and therapy, and is meant in no way to substitute for an individual patient assessment based upon the healthcare provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient.

Drugs and Doses
When prescribing medications, the health professional is advised to check the prescribing information accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. The CARE: Lupus Program has been independently planned by the Self-Assessment Program Development Group under the Continuous Professional Development Committee, and the ACR Committee on Education.

CARE Lupus Development Faculty Disclosures
View ACR’s ACCME disclosure practices >

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

1.Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
2.Research grants
3.Employment (full or part-time)
4.Ownership or partnership
5.Consulting fees or other remuneration (payment)
6.Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
7.Receipt of royalties
8.Speakers' bureau

The faculty reported the following disclosures:

Name of Individual

Name of Commercial Interest

Sarah Chisolm, MD, MPH


Megan Clowse, MD, MPH

UCB5, Pfizer2, Janssen2

Jason Cobb, MD

Abbvie2, MedImmune2, American Society of Nephrology2

Mary Anne Dooley, MD, MPH

GSK5,8, Lupus Foundation of America6, Aurinia5, Biogenidek5, UCB5, EMD Serono5, Medimmune5, Lily5, Genentec5, Lupus Clinical Trials Consortium6, BMS9

Candace Feldman, MD, MPH


Joanne Michelle Kahlenberg, MD, PhD


Karen Law, MD


S. Sam Lim, MD, MPH


Amanda Sammut, MD


Corporate Support

The production of this activity was supported by Grant Number 1 CPIMP141065-01-00 from the U.S. Department of Health and Human Services Office of Minority Health (HHS, OMH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS, OMH. No commercial support was obtained.